NAUT Earnings & Financial Statements
Nautilus Biotechnology, Inc.
$2.16
+$0.11(+5.37%)
56
Overall
60
Value
91
Tech
18
Quality
Market Cap
$274.87M
Volume
8.15M
52W Range
$0.84 - $4.31
Target Price
$3.83
NAUT earnings and financial statements: Nautilus Biotechnology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NAUT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $286.77M | - |
| Cost of revenue | - | - | - | $234.82M | - |
| Operating income | -$66.84M | -$81.48M | -$76.15M | -$93.36M | -$63.62M |
| EBITDA | -$62.16M | -$77.18M | -$62.05M | -$83.23M | -$60.20M |
| Net income | -$59.00M | -$70.78M | -$63.67M | -$105.40M | -$57.92M |
| EPS (diluted) | $-0.47 | $-0.56 | $-0.51 | $-3.34 | $-0.46 |
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $191.11M | $242.74M | $305.56M | $163.53M | $350.05M |
| Total liabilities | $34.14M | $34.01M | $40.21M | $102.23M | $35.13M |
| Shareholders’ equity | $156.97M | $208.73M | $265.35M | $61.30M | $314.92M |
| Cash and equivalents | $12.39M | $27.65M | $19.40M | $17.36M | $114.52M |
| Long-term debt | $26.19M | $26.38M | $31.09M | $42.95M | $28.34M |
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$50.70M | -$59.15M | -$51.71M | $1.34M | -$45.81M |
| Capital expenditure | -$1.28M | -$2.12M | -$2.44M | -$12.62M | -$2.32M |
| Free cash flow | -$51.97M | -$61.27M | -$54.15M | $1.34M | -$48.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAUT | $2.16 | +5.4% | 8.15M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Nautilus Biotechnology, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW